Research Activity
FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares
FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune
Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T
Wugen; CAR-T; allogeneic; off-the-shelf therapy; fratricide-resistant; funding; pivotal trial; T-cell malignancies
Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer
Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial
Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile
Vinay Prasad; FDA; return; Center for Biologics Evaluation and Research (CBER); fewer titles; lower profile; gene therapy; vaccine regulation
Who Is Making AI Work in Drug R&D in 2025?
AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency
Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships
AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration
Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch
Appia Bio; cell therapy; biotech shutdown; funding challenges; clinical trials; Kite Pharma partnership; oncology; biotech closures; IND application
Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success
Eli Lilly; GLP-1 pill; orforglipron; obesity; type 2 diabetes; FDA approval; weight loss; clinical trial
Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China
Akeso; Phase 3 trials; gumokimab; manfidokimab; ankylosing spondylitis; atopic dermatitis; regulatory submission; China; autoimmune diseases; clinical trial results
Argenx Prepares FDA Filing to Expand Vyvgart Use in Myasthenia Gravis After Late-Stage Trial Win
Argenx; Vyvgart; FDA approval; myasthenia gravis; prefilled syringe; self-injection; chronic inflammatory demyelinating polyneuropathy; generalized myasthenia gravis; clinical trial